Flamma Enters into An Agreement with Gilead's Veklury

Pharma Tech Outlook: Pharma Tech Magazine

Flamma Enters into An Agreement with Gilead's Veklury

By Pharma Tech Outlook | Friday, November 13, 2020

Kenneth Drew, Ph.D., VP, Flamma USA

Flamma continues the manufacturing partnership of Gilead’s Veklury for Covid-19 to be an active partner in developing path-breaking treatments.

Chignolo d'Isola, Italy: Flamma SpA, an eminent Contract Development and Manufacturing Organization (CDMO) that manufactures and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry enters into an agreement with Gilead to be part of the community of manufacturers contributing to the Veklury (remdesivir) supply chain. Flamma will continue to utilize its sites in Italy and China to power its need for necessary compounds to aid COVID-19 patients in need.

The Flamma team has strived to offer continuous manufacturing support for remdesivir, maintaining timelines for ongoing and upcoming projects due to the international and local needs. “This pandemic brought forth many challenges but Flamma responded to all of them with dedication and a team spirit by working tirelessly to be a part of the pharmaceutical supply chain to help those in need,” exclaims Kenneth Drew, Ph.D., VP Flamma, USA.

During the Covid-19 crisis, Flamma in Italy and China have continued producing essential molecules that are vital to help fight the virus. It showed commitment to not only customers but employees and to be a top-class organization. Flamma is proud of the opportunity to help Gilead and remdesivir in the battle against Covid-19 and continue to do all the company can to be an active partner in the development of treatments.

The company offers expertise for assisting its clients in early phase development and large-scale manufacturing. Flamma prides itself on the quality of customer service they deliver, working with clients to remediate problems like completing a project earlier than initially planned to meet a client’s deadline. Superior service and flexibility are what sets Flamma apart from the competition. Committed to delivering a fair price and on-time delivery while maintaining specifications and quality, Flamma has received several awards as a ground-breaking CMO.  “Flamma is a trusted partner that helps accelerate the supply chain of pharma companies working to develop small molecules drugs,” adds Kenneth Drew.

Flamma was featured in Pharma Tech Outlook as one of the Top 10 CMOs in Europe.

Weekly Brief

Read Also